Status: Not yet recruiting
IKS04 Regimen in Advanced Solid Tumors That Express CA242
This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further evaluation in expansion (RDE). The regimen includes Isumab04 (unconjugated antibody) followed by the IKS04 antibody-drug conjugate, both directed against the CA242 (CanAg) tumor-associated antigen and administered intravenously (IV) in patients with advanced solid cancers.
Participants needed: 120
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Iksuda Therapeutics Ltd.Updated: Jul 31, 2026Locations: 4
Eligibility criteria
Advanced or metastatic CRC, BTCs, GEA, and PDAC that is histologically or cytolo... [+12]
Significant symptomatic chronic obstructive pulmonary disease (COPD), as assesse... [+18]